UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).
UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).
On September 4, 112, our company received the official Establishment Inspection Report (EIR) issued by the United States Food and Drug Administration (FDA).
The inspection covered our Hsinchu plant from May 25 to June 6, 112, and the results indicated that UBI Pharma's Hsinchu plant passed the FDA's routine cGMP inspection. This marks the sixth successful inspection by the FDA for our company.
cGMP, or current Good Manufacturing Practice, is an international standard aimed at ensuring the quality, safety, and efficacy of pharmaceutical products. This inspection underscores our commitment to providing high-quality pharmaceutical products to meet customer needs.
